חוב לטווח קצר להון עצמי CytoMed Therapeutics (GDTC)

This price chart for CytoMed Therapeutics (GDTC) reflects a debt-to-equity ratio of 0.02. The Singapore-based business develops NK-cell therapies for oncology centers, targeting the global medical segment. Efficiency is enhanced by outsourcing trials to external CRO networks, which minimizes risks. Meanwhile, unique cell modification methods ensure seamless production scaling and global market capture.

This ratio compares the volume of liabilities with a maturity of up to one year against total equity, determining the company's degree of dependence on short-term debt financing. By analyzing the current short-term debt to equity value, an investor assesses liquidity risk, which is critical for CytoMed Therapeutics (GDTC) when implementing costly robotic biochemical screening systems to accelerate preclinical trials.